DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio
n

Tuesday, 15 September 2015

Braja Sundar Pradhan




DR BRAJA SUNDAR PRADHAN
.

Helvetica is founded by Dr Braja Sundar Pradhan in the year 2000. Dr Pradhan has synthetic organic chemistry background and completed doctoral studies under the supervision of renowned organic chemist, Professor Ian Flemming, University of Cambridge, United Kingdom.

The core area of strength of the company is to design and develop non-infringing synthetic routes to pharmaceutical and speciality chemicals. Depending on the needs of its clients, the company also undertakes manufacturing to provide chemicals from kilogram to ton scale. Helvetica is an export driven organization and exports high quality speciality chemicals to Europe and the USA.

Helvetica works in a partnership with its clients to provide services and products in a strictly confidential and exclusive manner maintaining highest standard and total quality assurances.

Publication numberUS20110263870 A1
Publication typeApplication
Application numberUS 13/091,717
Publication dateOct 27, 2011
Priority dateApr 23, 2010
InventorsBraja Sundar Pradhan
Original AssigneeHelvetica Industries (P) Limited




MYSELF WITH HIM IN CAMBRIDGE UK

Patent number: 8664417
Abstract: The invention provides for a process for the preparation of a silylferrocene compound, comprising the steps of treating ferrocene with a 4-chloroalkyryl chloride in the presence of an lewis acid catalyst and an organic solvent to obtain the acylated product, reducing the acylated product to obtain the 4-chloralkylferrocene, treating the 4-chloroalkylferroce with a metal under Grignard reaction conditions to form its corresponding Grignard intermediate compound; and reacting with chloroalkylsilane in-situ to give the silylferrocene compound. The silylferrocene compound 4-(dimethylsilyl)butylferrocene can be prepared by the process of the invention.
Type: Grant
Filed: October 18, 2010
Issued: March 4, 2014
Assignee: CBZ Chemicals Limited
Inventor: Braja Sundar Pradhan

Figure US08664417-20140304-C00005
http://www.google.com/patents/US8664417


Patent number: 8278468
Abstract: The invention relates to a process for preparing furanose derivatives, to furanose intermediates used in said process and to the use of said derivatives in the manufacture of atorvastatin.
Type: Grant
Filed: September 23, 2011
Issued: October 2, 2012
Assignee: CBZ Chemicals Limited
Inventor: Braja Sundar Pradhan
 Example 1 1,2:5,6-Di-O-isopropylidene-3-O-(imidazole-1-sulfonyl)-α-D-glucofuranose (E1)
Figure US08278468-20121002-C00023
To a stirred solution of 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (250 g, 961.54 mmol) in anhydrous dichloromethane (3.59 lt), imidazole (440 g, 646 mmol) was added at 0 to −5° C. over a period of 0.5 h. The reaction mixture was stirred for 1 h at this temperature and then a solution of sulfuryl chloride (149 ml) in dichloromethane (20 ml) was added dropwise to the mixture. After 5 h at 0 to −5° C., the reaction mixture was allowed to warm to room temperature and stirred at this temperature until the reaction was complete as indicated by TLC.

The precipitated salt was filtered off and the filtrate was washed with water (3×1000 ml). The organic layer was then washed successively with 10% aqueous hydrochloric acid (10×1000 ml), water (1×1000 ml), saturated sodium bicarbonate solution (2×1000 ml), water (1×1000 ml) and finally with brine (2×1000 ml). The organic layer was dried over sodium sulphate and concentrated under reduced pressure to give the title product (E1) as a solid; yield: 320 g, 93%......http://www.google.com/patents/US8278468

Application number: 20120209019
Abstract: The invention provides for a process for the preparation of a silylferrocene compound, comprising the steps of treating ferrocene with a 4-chloroalkyryl chloride in the presence of an lewis acid catalyst and an organic solvent to obtain the acylated product, reducing the acylated product to obtain the 4-chloralkylferrocene, treating the 4-chloroalkylferroce with a metal under Grignard reaction conditions to form its corresponding Grignard intermediate compound; and reacting with chloroalkylsilane in-situ to give the silylferrocene compound. The silylferrocene compound 4-(dimethylsilyl)butylferrocene can be prepared by the process of the invention.
Type: Application
Filed: October 18, 2010
Issued: August 16, 2012
Inventor: Braja Sundar Pradhan
Patent number: 8115010
Abstract: The invention relates to a process for preparing furanose derivatives, to furanose intermediates used in said process and to the use of said derivatives in the manufacture of atorvastatin.
Type: Grant
Filed: June 12, 2008
Issued: February 14, 2012
Assignee: CBZ Chemicals Limited
Inventor: Braja Sundar Pradhan
Application number: 20120016135
Abstract: The invention relates to a process for preparing furanose derivatives, to furanose intermediates used in said process and to the use of said derivatives in the manufacture of atorvastatin.
Type: Application
Filed: September 23, 2011
Issued: January 19, 2012
Inventor: Braja Sundar PRADHAN
Application number: 20110263870
Abstract: The present invention relates to two novel pyrrole derivatives [3-Phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrole-1-yl]methyl(diphenyl)phosphine oxide and Diethyl [3-Phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrole-1-yl]methylphosphonate. These pyrrole derivatives can be used as intermediates for the synthesis of the anticholesterol drug atorvastatin.
Type: Application
Filed: April 21, 2011
Issued: October 27, 2011
Assignee: HELVETICA INDUSTRIES (P) LIMITED
Inventor: Braja SUNDAR PRADHAN
Application number: 20100179331
Abstract: The invention relates to a process for preparing furanose derivatives, to furanose intermediates used in said process and to the use of said derivatives in the manufacture of atorvastatin.
Type: Application
Filed: June 12, 2008
Issued: July 15, 2010
Inventor: Braja Sundar Pradhan

Process for the synthesis of silylferrocene compounds

www.google.com/patents/EP2491049A1?cl=en
App. - ‎Filed 18 Oct 2010 - ‎Published 29 Aug 2012 - ‎Braja Sundar Pradhan - ‎CBZ Chemicals Limited
The invention provides for a process for the preparation of a silylferrocene compound, comprising the steps of treating ferrocene with a ...
Overview - ‎Related - ‎Discuss

Process for the synthesis of 4-(dimethylsilyl) butylferrocene

www.google.com/patents/US8664417
Grant - ‎Filed 18 Oct 2010 - ‎Issued 4 Mar 2014 - ‎Braja Sundar Pradhan - ‎Cbz Chemicals Limited
The invention provides for a process for the preparation of a silylferrocene compound, comprising the steps of treating ferrocene with a ...
Overview - ‎Related - ‎Discuss

Furanose derivatives for the preparation of atorvastatin

www.google.com/patents/EP2170916B1?cl=en
Grant - ‎Filed 12 Jun 2008 - ‎Issued 11 Jan 2012 - ‎Braja Sundar Pradhan - ‎Cbz Chemicals Limited
The invention relates to a process for preparing furanose derivatives, to furanose intermediates used in said process and to the use of said ...
Overview - ‎Related - ‎Discuss

Process for the synthesis of silylferrocene compounds

www.google.com/patents/WO2011048615A1?cl=en
App. - ‎Filed 18 Oct 2010 - ‎Published 28 Apr 2011 - ‎Braja Sundar Pradhan - ‎Cbz Chemicals Limited
The invention provides for a process for the preparation of a silylferrocene compound, comprising the steps of treating ferrocene with a ...
Overview - ‎Related - ‎Discuss

Furanose derivatives

www.google.com/patents/US8278468
Grant - ‎Filed 23 Sep 2011 - ‎Issued 2 Oct 2012 - ‎Braja Sundar Pradhan - ‎Cbz Chemicals Limited
The invention relates to a process for preparing furanose derivatives, to furanose intermediates used in said process and to the use of said ...
Overview - ‎Related - ‎Discuss

Furanose Derivatives

www.google.com/patents/EP2380895A1?cl=en
App. - ‎Filed 12 Jun 2008 - ‎Published 26 Oct 2011 - ‎Braja Sundar Pradhan - ‎Cbz Chemicals Limited
The invention relates to a process for preparing furanose derivatives, to furanose intermediates used in said process and to the use of said ...
Overview - ‎Related - ‎Discuss

Furanose derivatives

www.google.com/patents/US8115010
Grant - ‎Filed 12 Jun 2008 - ‎Issued 14 Feb 2012 - ‎Braja Sundar Pradhan - ‎Cbz Chemicals Limited
The invention relates to a process for preparing furanose derivatives, to furanose intermediates used in said process and to the use of said ...
Overview - ‎Related - ‎Discuss


Furanose derivatives and their applications in synthesis ...

www.google.co.in/patents/WO2012032534A3?cl=en
App. - ‎Filed 8 Aug 2011 - ‎Published 2 Aug 2012 - ‎Thoomu Apparao - ‎Helvetica Industries (P) Limited
The present invention relates to compounds of formula XXII and their synthesis from furanose derivatives as shown hereunder. Compounds of ...
Overview - ‎Related - ‎Discuss

Process for preparing pregabalin

www.google.co.in/patents/WO2011016052A3?cl=en
App. - ‎Filed 2 Aug 2010 - ‎Published 31 Mar 2011 - ‎B. S. Pradhan - ‎Helvetica Industries (P) Limited
The invention relates to a process for preparing a compound of formula (I): wherein said process comprises hydrogenation of ...
Overview - ‎Related - ‎Discuss

Example 11
(-)-3-Aminomethyl-5-methylhexanoic acid (E11)
Figure imgf000019_0001
The racemic pregabalin of Example 10 was filtered, washed with cold dichloromethane and resolved with (SJ-mandelic acid using isopropanol-water (97:3) solvent system following the procedure of Marvin S. Hoekstra et. al., Organic Process Research and Development, 1997, 1, 26, to obtain the first batch of pregabalin Another batch of pregabalin was obtained from the filtrates of the first resolution following the procedure as detailed under:
The filtrates of the first resolution were combined and evaporated completely under reduced pressure to recover isopropyl alcohol, which was subsequently reused without any loss of either the purity or the yield of the final product, Pregabalin. The residue thus obtained was acidified with concentrated hydrochloric acid triggering the precipitation of the first batch of S(+)- Mandelic acid. The aqueous solution was then extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulphate and evaporated under reduced pressure to give another batch of S(+)- Mandelic acid as a white solid which was combined with the former and recycled in subsequent batches without any loss of either the purity or the yield of the final product, Pregabalin. The aqueous layer containing the amino acid enriched with the undesired isomer was evaporated under reduced pressure to a thick oil and basified with triethyl amine at -5 0C to 0 0C. Chloroform was then added to it at -5 0C to 0 0C and the mixture was maintained at this temperature for 1-2 h. The precipitated solid was filtered, washed with cold chloroform and air-dried overnight to give the amino acid enriched with the undesired isomer which was resolved with R (-) Mandelic acid repeating the procedure of Marvin S. Hoekstra et. al., Organic Process Research and Development, 1997, 1, 26; to obtain the undesired isomer of pregabalin. The filtrates of this resolution was combined and evaporated under reduced pressure to recover and recycle isopropyl alcohol. The residue thus obtained was subjected to the process of recovery of R (-) Mandelic acid and the racemic Pregabalin following the protocol mentioned in the preceding paragraph. R (-) Mandelic acid was recycled in subsequent batches without any loss of the yield or the purity of the undesired isomer of Pregabalin. The recovered racemic Pregabalin thus obtained was again resolved with S(+)- Mandelic acid repeating the Marvin S. Hoekstra et. al., Organic Process Research and Development, 1997, 1, 26, to obtain a second batch of Pregabalin.......http://www.google.com/patents/WO2011016052A2?cl=en


Process for preparing pregabalin

www.google.co.in/patents/EP2462106A2?cl=en
App. - ‎Filed 2 Aug 2010 - ‎Published 13 Jun 2012 - ‎B. S. Pradhan - ‎Helvetica Industries (P) Limited
The invention relates to a process for preparing a compound of formula (I): wherein said process comprises hydrogenation of a compound of ...
Overview - ‎Related - ‎Discuss

Novel pyrrole derivatives and their synthesis

www.google.co.in/patents/US20110263870
App. - ‎Published 27 Oct 2011 - ‎Braja Sundar Pradhan - ‎Helvetica Industries (P) Limited
The present invention relates to two novel pyrrole derivatives ...
Overview - ‎Related - ‎Discuss

Process for preparing pregabalin

www.google.co.in/patents/US20120142949
App. - ‎Filed 2 Aug 2010 - ‎Published 7 Jun 2012 - ‎B. S. Pradhan - ‎Helvetica Industries (P) Limited
The invention relates to a process for preparing a compound of formula (I): wherein said process comprises hydrogenation of a compound of ...
Overview - ‎Related - ‎Discuss



Professor Ian Flemming, University of Cambridge, United Kingdom
Ian Fleming is an Emeritus Professor in the Department of Chemistry in the University of Cambridge, and an Emeritus Fellow of Pembroke College



///////

Dr. Muppala Raju



Dr.Muppala S. Raju
Vice President, Chemistry

DavosPharma Tech Ops Team
davo79.wix.com
msraju@davos.com

A Leading Provider of Discovery, Chemistry and Formulation Services

Dr. Muppala Raju joined DavosPharma in 1995. He is responsible for the development of DavosPharma' business activities in India.
Dr. Muppala Raju joined DavosPharma in 1995. He is responsible for the development of DavosPharma' business activities in India. Dr. Raju is also head of chemistry atDavosPharma where he directs the process development of all contracted projects at DavosPharma' worldwide custom manufacturers.
Prior to joining DavosPharma, Dr. Raju held several positions including Manager of Chemical Process R&D for Celgene Corporation. He was also a Research Scientist for Rhône-Poulenc Research Center, Research Chemist for PPG Industries and held post doctoral positions at the University of Iowa and Rockefeller University.
Dr. Raju has co-authored fifteen research publications and has been issued six patents.
He holds a Ph.D. from Rice University and an MBA from Kent State University.

Employment History

  • Vice President, Chemistry, Davos Chemical Corporation
  • Head of Chemistry, Davos Chemical Corporation
  • Manager of Chemical Process Research and Development, Celgene Corporation
  • Post Doctoral Positions, Rockefeller University
  • Post Doctoral Positions, University of Iowa
  • Research Scientist, Rhône-Poulenc Research Center

Education

  • MBA, Kent State University
  • Ph.D., Rice University


Barry Robins. President. Davos Pharma
Davos Chemical Corporation provides chemistry and pharmaceutical services for biotechs and pharmaceutical companies in United States, Europe, and Asia. The company offers drug substance and drug products in the areas of preclinical/clinical supply, commercial manufacture, and cytotoxics and other compounds; documentation preparation and support services; oral and parenteral clinical trial materials; synthesized materials, including APIs and intermediates; analytical services, such as methods development, testing, and validation; preformulation and formulation development services; chemistry development and optimization services; and medicinal chemistry and biology discovery services.
600 East Crescent AvenueUpper Saddle RiverNew Jersey07458United States
View Map
(201) 995-0070(201) 995-0071Fax
Map of upper saddle river





//////

PRIYANKA PRABHU OF ICT, MUMBAI, INDIA GETS BEST POSTER AWARD




PRIYANKA PRABHU OF ICT, MUMBAI,  INDIA
Ph.D (Tech) (Senior Research Fellow) in Pharmaceutics at Institute of Chemical Technology, Mumbai, India

Gets "BEST POSTER AWARD" for poster titled “Artemether-Lumefantrine loaded Nanostructured Lipid Carriers (NLC) for treatment of cerebral malaria”at the 2nd International Conference on Nanotechnology Based Formulations- NanoPharmaceuticals, held on 10-11 September, 2015, at Hyderabad organized by Select Biosciences India Private Limited.


She works with Dr Vandana Patravale,
Professor Of Pharmaceutics at ICT
Vandana Patravale



Prof. Vandana B. Patravale

Room A-255, 1st Floor
Department of Pharmaceutical Sciences and Technology
Institute of Chemical Technology
N. P. Marg, Matunga
Mumbai 400019
India

Phone: +91 22 3361 2217
Fax: +91 22 3361 1020





LINKS

https://in.linkedin.com/pub/priyanka-prabhu/32/699/b32

https://www.facebook.com/priyanka.prabhu.714

 

Education







Institute of Chemical Technology, Mumbai, India

Master of Pharmacy (M. Pharm)., Drug Delivery Technology, Distinction






Bombay College of Pharmacy

Bachelor of Pharmacy (B.Pharm.), Pharmaceutical Sciences, Distinction

Publications

 






NANODRUG DELIVERY BASED ON COMBINATION THERAPY FOR TREATING PARASITE INFECTIONS

India 3567/MUM/2013
Filed November 13, 2013






Lipid Based Drug Delivery Systems

Book Chapter in the book: "Recent Trends in Novel Drug Delivery", Edited by N Udupa and Srinivas Mutalik, Prism Books Pvt. Ltd.
2014






Potential of Nanocarriers in Antigen Delivery: A Path to Successful Vaccine Delivery

Nanocarriers
February 2014






The Upcoming Field of Theranostic Nanomedicine: An Overview(Link)

Journal of Biomedical Nanotechnology, American Scientific Publishers
December 2012






Nanocarriers for Effective Topical Delivery of Anti-Infectives(Link)

Current Nanoscience, Bentham Science
September 2012






Novel Targets for Malaria Therapy(Link)

Current Drug Targets, Bentham Science
December 2011






Lipid Nanocarriers for Topical Anti-cancer Therapy: An Update

Book chapter in the book "Lipid Nanocarriers in Cancer Diagnosis and Therapy", Edited by Eliana B. Souto, Published by iSmithers
August 4, 2011

Honors & Awards

Best Poster Award

Select Biosciences India Private Limited

Best Poster Award for research work titled "Artemether-Lumefantrine loaded Nanostructured Lipid Carriers (NLC) for treatment of cerebral malaria" at the 2 nd International Conference on Nanotechnology Based Formulations- NanoPharmaceuticals, organised by Select Biosciences India Private Limited, held on 10-11 September, 2015, at Hyderabad.

Third Prize for Preclinical Oral Presentation

South Asian Chapter of American College of Clinical Pharmacology

Awarded "Third Prize for Preclinical Oral Presentation" on research work titled "Nanostructured Lipid Carriers (NLC) OF Artemether-Lumefantrine combination for oral malaria therapy" at the Eighth International Annual Conference on "Translational Clinical Pharmacology Research in Drug Development" organised by South Asian Chapter of American College of Clinical Pharmacology

Grand Challenges Exploration Round 11

Bill and Melinda Gates Foundation

Actively Involved in concept proposal for a nanovaccine for nasal immunization against brucellosis using green technology. The proposal won a grant of 100000 USD in the GRAND CHALLENGES EXPLORATIONS ROUND 11, BILL & MELINDA GATES FOUNDATION AWARDS.

Bombay College of Pharmacy SILVER JUBILEE AWARD

Bombay College of Pharmacy

Received Bombay College of Pharmacy SILVER JUBILEE AWARD for standing SECOND in Third year B.Pharm

Sir Ratan Tata Trust Scholarship

Sir Ratan Tata Trust

Received Sir Ratan Tata Trust Scholarship for securing a DISTINCTION in Second year B.Pharm

Sir Ratan Tata Trust Scholarship

Sir Ratan Tata Trust

Received Sir Ratan Tata Trust Scholarship for securing a DISTINCTION in First year B.Pharm

Indian Pharmaceutical Association (IPA) Maharashtra State Branch Scholarship

Indian Pharmaceutical Association
Received Indian Pharmaceutical Association (IPA) Maharashtra State Branch Scholarship and a medal for standing FIRST in B.Pharm Admissions.

 

 Her group
//////////